Brief: Morphosys' Licensing Partner, GSK Provides Update On Contrast Phase Iii Program For Otilimab In Moderate To Severe Rheumatoid Arthritis

Morphosys AG

27/10/2022 07:53

Oct 27 (Reuters) - MORPHOSYS AG  MORG.DE :
    * GSK, MORPHOSYS’ LICENSING PARTNER, PROVIDES UPDATE ON
CONTRAST
PHASE III PROGRAM FOR OTILIMAB IN MODERATE TO SEVERE RHEUMATOID
ARTHRITIS
    * (FSE: MOR; NASDAQ: MOR) ANNOUNCED TODAY THAT ITS LICENSING
PARTNER, GSK PLC (LSE/NYSE: GSK), PROVIDED AN UPDATE ON CONTRAST
PHASE III PROGRAM FOR OTILIMAB AS A POTENTIAL TREATMENT OF
MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)
    * CONTRAST PHASE IIL PROGRAM ENROLLED A BROAD RANGE OF
DIFFICULT-TO-TREAT PATIENTS WHO HAD AN INADEQUATE RESPONSE TO OR
COULD NOT TOLERATE AVAILABLE TREATMENTS
    * CONTRAST-1 AND CONTRAST-2 MET THEIR PRIMARY ENDPOINTS OF A
STATISTICALLY SIGNIFICANT ACR20 (AMERICAN COLLEGE OF
RHEUMATOLOGY CRITERIA) RESPONSE VERSUS PLACEBO AT WEEK 12 IN
PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE (CONTRAST-1)
AND CONVENTIONAL SYNTHETIC OR BIOLOGIC DISEASE MODIFYING
ANTIRHEUMATIC DRUGS (DMARDS) (CONTRAST-2)
    * GSK IS PLANNING TO SUBMIT FULL RESULTS FROM CONTRAST PHASE
III
PROGRAM FOR PUBLICATION IN 2023

Source text for Eikon:  ID:nEQ4FrFSka 
Further company coverage:  MORG.DE 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))